Skip to content

Andrew A Nierenberg

Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.

2 papers in the library · 3 citations · publishing 2024-2026

Papers

Does baseline psychiatric symptom severity predict well-being improvement in low-intensity mindfulness interventions?

Psychiatry research communications September 1, 2024 Alexandra K Gold, Dustin J Rabideau, Daniel Nolte et al. 2 citations

People with more severe anxiety, depression, or social difficulties initially improved in well-being during low-intensity mindfulness interventions (three or eight sessions), but those with worse symptoms tended not to sustain improvements and rebounded toward baseline during follow-up. The findings suggest that such brief mindfulness-based treatments can still be clinically useful for individuals with more severe mental health symptoms, as they experienced initial improvement, but offering longer-duration treatment might prevent symptom rebounding.

Ketamine Infusions and Rapid Reduction of Suicidal and Depressive Symptoms in Major Depressive Episode: A Systematic Review and Meta-Analysis.

JAMA psychiatry July 1, 2026 Sung Ryul Shim, Hye Su Jeong, Tanner J Bommersbach et al. 1 citation

A systematic review and meta-analysis of 26 randomized clinical trials with 1,166 patients experiencing a major depressive episode found that intravenous ketamine infusions significantly reduce suicidal and depressive symptoms in the acute phase. A single ketamine infusion lowered suicidal symptoms at 24 hours and at 1 month, and repeated infusions produced similar reductions. Depressive symptoms decreased significantly from 4 hours through 1 week after a single infusion and after repeated infusions. Serious adverse events were unrelated to the interventions, and other side effects were transient. Longer-term outcomes remain unclear.